Mavacoxib
4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
También conocido como: Trocoxil · mavacoxibum · PHA 739,521 · UNIIYFT7X7SR77
Revisado por el equipo veterinario de VetSheetActualizado 5 abr 2026Referencia veterinaria basada en la evidencia
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Dosis por especie
🌎 NA — North America🌍 EU — Europe
Perros
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Pain and inflammation associated with degenerative joint disease in dogs aged 12 months or more in cases where continuous treatment exceeding one month is indicated | 2 mg/kg PO given immediately before or with the dog's main meal. The treatment should be repeated 14 days later; thereafter the dosing interval is one month. | PO | Day 1, Day 14, then monthly | A treatment cycle should not exceed 7 consecutive doses (6.5 months). | 🌎 NA |
| Pain and inflammation associated with degenerative joint disease (osteoarthritis) | 2 mg/kg | PO | q14d for 2 doses, then q1month | Maximum of 7 doses total | 🌍 EU |
- Pain and inflammation associated with degenerative joint disease in dogs aged 12 months or more in cases where continuous treatment exceeding one month is indicated: Care should be taken to ensure that the tablet is ingested. THIS IS not a daily NSAID.
- Pain and inflammation associated with degenerative joint disease (osteoarthritis): Should be given immediately before or with the dog's main meal. Treatment can potentially be re-started after a 1-month break from dosing.
Gatos
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Any | Do not use | PO | N/A | N/A | 🌍 EU |
- Any: Contraindicated in cats.
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Resumen
El mavacoxib es un antiinflamatorio no esteroideo (AINE) de la clase de los coxibs, único y de acción ultra prolongada. A diferencia de los AINE tradicionales de administración diaria, el mavacoxib está diseñado para administrarse mensualmente, lo que lo convierte en una excelente opción para pacientes cuyos propietarios tienen dificultades para cumplir con una pauta de dosificación diaria.
Perla clínica: Debido a su vida media excepcionalmente larga (promedio de 16-17 días), cualquier efecto adverso puede persistir durante semanas después de suspender el fármaco. Por lo tanto, una selección cuidadosa del paciente es fundamental, y generalmente se reserva para el manejo de la osteoartritis crónica en lugar del dolor agudo.
Mecanismo de acción
Mavacoxib is a COX-2 selective inhibitor (coxib).
- Arachidonic Acid Cascade: It selectively inhibits the cyclooxygenase-2 (COX-2) enzyme → decreases the production of pro-inflammatory prostaglandins (such as PGE2) → reduces pain, inflammation, and fever.
- COX-1 Sparing: At therapeutic dosages, it relatively spares COX-1, the constitutive enzyme responsible for synthesizing prostaglandins that protect the gastric mucosa, support platelet function, and maintain normal renal blood flow. However, COX-selectivity is relative and can be lost at higher doses or in susceptible individuals.
Seguridad y advertencias
Contraindicaciones
- Dogs less than 12 months of age
- Dogs less than 5 kg body weight
- Gastrointestinal disorders including ulceration and bleeding
- Evidence of a hemorrhagic disorder
- Impaired renal or hepatic function
- Cardiac insufficiency
- Hypersensitivity to mavacoxib, sulfonamides, or excipients
- Pregnant, breeding, or lactating animals
- Dehydrated, hypovolemic, or hypotensive animals
- Dehydrated, hypovolaemic, or hypotensive patients
- Gastrointestinal disease or ulceration
- Blood clotting disorders
- Liver disease (prolongs metabolism and causes accumulation)
- Renal disease (requires careful evaluation, generally avoid)
- Pregnant or lactating animals
- Dogs < 12 months of age
- Dogs < 5 kg body weight
- Cats
Efectos adversos
- Inappetence
- Diarrhea
- Depression
- Gastrointestinal ulceration or bleeding
- Vomiting and diarrhoea
- Renal toxicity (especially if dehydrated or hypotensive)
- Hepatic accumulation (in poor metabolizers)
- Theoretical risk of precipitating cardiac failure
Precauciones
Do not use concomitantly with glucocorticoids or other NSAIDs. Do not administer other NSAIDs within 1 month of the last administration of mavacoxib. Avoid use in any dehydrated, hypovolemic, or hypotensive animal, as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic medicinal products should be avoided. Animals should not become dehydrated when receiving this or other NSAIDs.
Interacciones farmacológicas
NSAIDs can reduce effects on blood pressure and potentially reduce renal blood flow, increasing the risk for renal injury.
May increase the risk of gastrointestinal toxicity (ulceration, bleeding, vomiting, diarrhea). Long washout periods are warranted when switching.
May increase the risk of gastrointestinal toxicity (ulceration, bleeding, vomiting, diarrhea). Concurrent use is contraindicated.
NSAIDs may increase serum levels of digoxin.
May increase plasma levels of mavacoxib (extrapolated from celecoxib data in humans).
NSAIDs may reduce saluretic and diuretic effects.
Serious toxicity has occurred when NSAIDs have been used concomitantly; use together with extreme caution.
May enhance the risk of nephrotoxicity development.
May increase the risk of gastrointestinal toxicity. Do not administer other NSAIDs within 1 month of the last administration of mavacoxib.
Increased risk of severe gastrointestinal ulceration and bleeding.
Increased risk of nephrotoxicity.
Synergistic risk of acute kidney injury.
Monitorización
- Baseline and periodic CBC and serum chemistry (including BUN/serum creatinine, and liver function assessment)
- Baseline history and physical
- Efficacy of therapy
- Adverse effect monitoring via client
- Baseline and periodic renal function (BUN, Creatinine, SDMA, USG)
- Baseline and periodic hepatic function (ALT, ALP, Bilirubin)
- Clinical signs of GI ulceration (vomiting, melaena, anorexia)
- Hydration status and blood pressure (especially during anaesthesia)
Farmacocinética
Vida media
Absorción
Average bioavailability after oral dosing is about 46% when fasted, but nearly doubles (87%) when given with food. Peak levels occur in about 11 hours.
Distribución
Apparent volume of distribution (steady-state) averaged 1.6 L/kg. Highly bound to canine plasma proteins (98%).
Metabolismo
Primarily cleared by biliary excretion.
Eliminación
Total body clearance is a very low 2.7 mL/hour/kg.
Sobredosis
In safety studies, repeated doses of 5 and 10 mg/kg did not demonstrate adverse events. At 15 mg/kg, vomiting, softened/mucoid feces, and decreased renal function were noted. Doses of 25 mg/kg caused GI ulceration, with one fatality from GI perforation and peritonitis.
- Management: Manage as with other NSAID toxicity (emetics, activated charcoal, GI protectants, fluid diuresis).
- Important: Because of the drug's very long duration of effect, prolonged monitoring and treatment may be required. Consulting a veterinary poison center is highly recommended.
Productos disponibles
Formulaciones
- Oral chewable tablets
- 6 mg chewable tablet
- 20 mg chewable tablet
- 30 mg chewable tablet
- 75 mg chewable tablet
- 95 mg chewable tablet
Veterinario
- Mavacoxib Oral Chewable Tablets: 6 mg, 20 mg, 30 mg, 75 mg, & 95 mg (Trocoxil)
- Trocoxil 6 mg chewable tablets
- Trocoxil 20 mg chewable tablets
- Trocoxil 30 mg chewable tablets
- Trocoxil 75 mg chewable tablets
- Trocoxil 95 mg chewable tablets
Estado regulador
Authorized for use in dogs >= 12 months old.
POM-V classification.
Sin datos reguladores para: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Almacenamiento y estabilidad
Store in the original packaging at room temperature out of reach of pets and children.
Información para el cliente
ADVERTENCIA CRÍTICA: Este NO es un medicamento de uso diario. Adminístrelo exactamente según las indicaciones de su veterinario (típicamente una dosis el día 1, el día 14 y luego estrictamente una vez al mes). No administre dosis adicionales.
- Administrar con comida: Debe administrarse con la comida principal del día del perro. El fármaco se absorbe mucho mejor desde el estómago si se administra con alimento.
- Vigile los efectos secundarios: Contacte a su veterinario de inmediato si nota pérdida de apetito, vómitos, heces con sangre o de color oscuro/alquitranado, cambios en el comportamiento o cambios en la ingesta de agua o la micción. Nota: Debido a que este fármaco permanece mucho tiempo en el cuerpo, los efectos secundarios podrían ocurrir semanas después de la última dosis administrada.
- Almacenamiento seguro: Estos comprimidos masticables son altamente palatables para los perros. Guárdelos estrictamente fuera del alcance de todos los animales y niños para evitar una sobredosis accidental.
La referencia de medicamentos de VetSheet está destinada a profesionales veterinarios autorizados como ayuda para la toma de decisiones clínicas, no como sustituto del criterio profesional ni del prospecto actual del fabricante.